Health Care [ 4/12 ] | Pharmaceuticals [ 23/75 ]
NASDAQ | Common Stock
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.
The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.
In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform.
The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 26 | -0.26 Decreased by -61.79% | -0.13 Decreased by -100.00% |
| Nov 5, 25 | -0.14 Decreased by -7.69% | -0.14 |
| Aug 11, 25 | -0.14 Decreased by -366.67% | -0.17 Increased by +17.65% |
| May 5, 25 | -0.22 Decreased by -31.47% | -0.08 Decreased by -179.38% |
| Mar 3, 25 | -0.16 Decreased by -46.09% | -0.13 Decreased by -21.28% |
| Nov 4, 24 | -0.13 Decreased by -333.33% | -0.13 |
| Aug 6, 24 | -0.03 Increased by +70.00% | -0.12 Increased by +75.00% |
| May 7, 24 | -0.17 Decreased by -41.67% | -0.08 Decreased by -112.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 13.02 M Increased by +9.67% | -31.86 M Decreased by -86.81% | Decreased by -244.79% Decreased by -70.33% |
| Sep 30, 25 | 12.81 M Decreased by -5.43% | -15.45 M Decreased by -34.21% | Decreased by -120.61% Decreased by -41.91% |
| Jun 30, 25 | 10.00 M Decreased by -50.23% | -13.55 M Decreased by -393.55% | Decreased by -135.44% Decreased by -891.69% |
| Mar 31, 25 | 8.72 M Decreased by -27.65% | -22.93 M Decreased by -78.75% | Decreased by -262.96% Decreased by -147.07% |
| Dec 31, 24 | 11.87 M Decreased by -10.14% | -17.05 M Decreased by -110.27% | Decreased by -143.72% Decreased by -134.00% |
| Sep 30, 24 | 13.54 M Increased by +4.15% | -11.51 M Decreased by -465.55% | Decreased by -84.99% Decreased by -443.00% |
| Jun 30, 24 | 20.10 M Increased by +51.79% | -2.75 M Increased by +52.61% | Decreased by -13.66% Increased by +68.78% |
| Mar 31, 24 | 12.05 M Increased by +8.25% | -12.83 M Decreased by -259.00% | Decreased by -106.43% Decreased by -246.88% |